The VP and Chief Culture Officer of NeoGenomics is Exercising Options

By Carrie Williams

Today, the VP and Chief Culture Officer of NeoGenomics, Jennifer Balliet , exercised options of NeoGenomics (NASDAQ: NEO) for $146.1K.

Following Jennifer Balliet’s last NEO Sell transaction on August 25, 2017, the stock climbed by 2.0%. In addition to Jennifer Balliet, 2 other NEO executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on NeoGenomics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $63.42 million and quarterly net profit of $644K. In comparison, last year the company earned revenue of $61.68 million and had a GAAP net loss of $654K. Currently, NeoGenomics has an average volume of 365.3K.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $10.67, reflecting a 5.4% upside.

In the last 30 days, insiders have sold $1.03M worth of NEO shares and purchased $514.5K worth of NEO shares. The insider sentiment on NeoGenomics has been neutral according to 21 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services.